Infections

All Conditions

Symptoms and General Pathology

Neoplasms

Digestive System Diseases

Rare Diseases

Communicable Diseases

Stomach Neoplasms

Atrophy

Adenoma

Gastritis, Atrophic

Metaplasia

Gastritis

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Pathological Conditions, Anatomical

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastroenteritis

Stomach Cancer

Subjects without Helicobacter pylori infection and without atrophy

Subjects with Helicobacter pylori infection and without atrophy

Subjects with Helicobacter pylori infection and with atrophy

Subjects without Helicobacter pylori infection and with atrophy

Sun-Young Lee, MD

Serum pepsinogen (PG) levels are considered reliable markers for progression of atrophic gastritis with a stepwise reduction in the serum PG I level or PG I/II ratio. A combination of serum PG levels and Helicobacter pylori serology are used as a biomarker strategy for detection of individuals at increased risk of gastric neoplasm based on Correa's hypothesis. The investigators aimed to uncover whether this combination method could predict the risk of gastric neoplasms and the progression of chronic atrophic gastritis after 3 years. All the participants will be followed for an expected average of 3 years.

According to the Correa's hypothesis, the combination method using serum pepsinogen levels and serum Helicobacter pylori antibody would predict the risk and cell type of gastric neoplasm. However, in endemic regions of H. pylori infection such as in East Asian countries (Korea, Japan, and China), most of the aged population are have current or had past H. pylori infection. Therefore, in this study, we are going to uncover whether the risk of gastric neoplasm is significantly higher in the atrophy(+)/H. pylori(-) group followed by atrophy(+)/H. pylori(+), atrophy(-)/H. pylori(+), and atrophy(-)/H. pylori(-) groups. In addition, we are going to investigate whether those slow-growing gastric neoplasms such as differentiated gastric cancers with Lauren's intestinal type and gastric adenoma are more commonly developed in atrophy group following the Correa's hypothesis, whereas rapid-growing gastric neoplasms such as poorly-cohesive carcinoma or undifferentiated gastric cancers with Lauren's diffuse type are more commonly developed in the subjects without atrophy. Taken as a whole, our study result will provide an evidence whether this biomarker strategy are useful for the detection of individuals at increased risk of gastric neoplasm.

Serum for Helicobacter pylori antibody and pepsinogen levels Gastric biopsy for the diagnosis of intestinal metaplasia, atrophy, inflammatory cells, Helicobacter pylori, and the presence of gastric neoplasm if any.

Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years

Significance of Helicobacter Pylori Infection and Pepsinogen Levels on the Prognosis of Atrophic Gastritis - Observational Study

Presence of Helicobacter pylori infection

Degree of gastric atrophy measured by serum pepsinogen I and II levels

Konkuk University Medical Center

Associate professor

Patients who were diagnosed with gastric cancer

Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease

Officials Officials, Officials

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is high. In addition, the investigators attempted to investigate the interaction among the several risk factors including OLGA or OLGIM staging system for the risk of GC to help establish surveillance strategy.

OLGA and OLGIM Stage System for Gastric Cancer

The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification

National Clinical Research Coordination Center, Seoul, Korea

Seoul National University Bundang Hospital

Professor

OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)

OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)

OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)

diagnostic value of pepsinogen for severe atrophy and gastric cancer

pepsinogen

Yuling Tong, Dr.

Yi Zhao, Master

Xuan Huang

Tong Huang

Based on the gastric cancer database established earlier, this project explored the PG standard suitable for Chinese people, and further explored the establishment of machine learning model to stratify gastric cancer risk in the population, guide the frequency of gastroscopy screening, and extract important gastric cancer risk factors from it.Establish electronic health records of gastric organs, track the development and outcome of gastric diseases through deep learning method, in order to predict the development and outcome of gastric diseases;Then, the simulation hypothesis deductive method is used to compare the outcomes that may be caused by different lifestyles with the help of deep learning model, so as to guide patients to develop a better lifestyle and explore the establishment of health management paths for gastric cancer patients and high-risk groups in China.

The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning

pepsinogen value for precanceous lesion and Gastric cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)

The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)

The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)

serum pepsinogen diagnosed gastric cancer and precanceous lesion

Zhenya Song, Dr.

Hongguang Wang

Hong Li

Lirong Gong

Hongbo Wu

Xueqiang He

Yinhu Luo

Hongwei Xu

Dong Wang

Hongzhi Xu

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China. We operated a multicenter cross-sectional study of subjects who underwent health checkup at nine International Healthcare Centers in China. All participants underwent gastroscopy and pathological examination, serum PG, 13C-urea breath test, and/or Hp serological current infection marker rapid test, all on the same day. PG related parameters were analyzed in different Hp subgroups and regions.

Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

China Health Promotion Foundation/the Second Affiliated Hospital of Zhejiang University, School of Medicine

cutoff values of pepsinogen level for GC and precancerous lesions in different regions in China and in different HP status

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years	NCT01824953	Gastric Neoplas... Gastric Cancer Gastric Adenoma Gastric Atrophy Intestinal Meta...		18 Years - 90 Years	Konkuk University Medical Center
OLGA and OLGIM Stage System for Gastric Cancer	NCT03380052	Stomach Neoplas... Atrophic Gastri... Intestinal Meta...		25 Years - 80 Years	Seoul National University Bundang Hospital
The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning	NCT04957407	Gastric Cancer Precancerous Le... Mechine Learnin...	pepsinogen	25 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer	NCT04989153	Gastric Cancer Precancerous Le... Helicobacter Py...	pepsinogen	25 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University

Spots Global Cancer Trial Database for pepsinogen

Every month we try and update this database with for pepsinogen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for pepsinogen

Every month we try and update this database with for pepsinogen cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for pepsinogen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.